000062851 001__ 62851
000062851 005__ 20201105083207.0
000062851 0247_ $$2doi$$a10.1515/cclm-2016-0382
000062851 0248_ $$2sideral$$a98532
000062851 037__ $$aART-2017-98532
000062851 041__ $$aeng
000062851 100__ $$aLlopis, M. A.
000062851 245__ $$aSpanish Preanalytical Quality Monitoring Program (SEQC), an overview of 12 years' experience
000062851 260__ $$c2017
000062851 5060_ $$aAccess copy available to the general public$$fUnrestricted
000062851 5203_ $$aPreanalytical variables, such as sample collection, handling and transport, may affect patient results. Preanalytical phase quality monitoring should be established in order to minimize laboratory errors and improve patient safety. A retrospective study (2001-2013) of the results obtained through the Spanish Society of Clinical Biochemistry and Molecular Pathology (SEQC) External quality assessment (preanalytical phase) was performed to summarize data regarding the main factors affecting preanalytical phase quality. Our aim was to compare data from 2006 to 2013 with a previously published manuscript assessing the 2001-2005 period. A significant decrease in rejection rates was observed both for blood and urine samples. For serum samples, the most frequent rejection causes in the first period were non-received samples (37.5%), hemolysis (29.3%) and clotted samples (14.4%). Conversely, in the second period, hemolysis was the main rejection cause (36.2%), followed by non-received samples (34.5%) and clotted samples (11.1%). For urine samples, the main rejection cause overall was a non-received sample (up to 86.1% of cases in the second period, and 81.6% in the first). For blood samples with anticoagulant, the number of rejections also decreased. While plasma-citrate-ESR still showed the highest percentages of rejections (0.980% vs. 1.473%, p<0.001), the lowest corresponded to whole-blood EDTA (0.296% vs. 0.381%, p<0.001). For the majority of sample types, a decrease in preanalytical errors was confirmed. Improvements in organization, implementation of standardized procedures in the preanalytical phase, and participation in a Spanish external quality assessment scheme may have notably contributed to error reduction in this phase.
000062851 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000062851 590__ $$a3.556$$b2017
000062851 591__ $$aMEDICAL LABORATORY TECHNOLOGY$$b7 / 30 = 0.233$$c2017$$dQ1$$eT1
000062851 592__ $$a1.114$$b2017
000062851 593__ $$aBiochemistry (medical)$$c2017$$dQ1
000062851 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000062851 593__ $$aClinical Biochemistry$$c2017$$dQ2
000062851 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000062851 700__ $$aBauça, J. M.
000062851 700__ $$aBarba, N.
000062851 700__ $$aÁlvarez, V.
000062851 700__ $$aVentura, M.
000062851 700__ $$aIbarz, M.
000062851 700__ $$aGómez-Rioja, R.
000062851 700__ $$aMarzana, I.
000062851 700__ $$0(orcid)0000-0002-7213-7095$$aPuente, J. J.
000062851 700__ $$aSegovia, M.
000062851 700__ $$aMartinez, D.
000062851 700__ $$aAlsina, M. J.
000062851 773__ $$g55, 4 (2017), 530-538$$pClin. chem. lab. med.$$tClinical Chemistry and Laboratory Medicine$$x1434-6621
000062851 8564_ $$s152892$$uhttps://zaguan.unizar.es/record/62851/files/texto_completo.pdf$$yVersión publicada
000062851 8564_ $$s124686$$uhttps://zaguan.unizar.es/record/62851/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000062851 909CO $$ooai:zaguan.unizar.es:62851$$particulos$$pdriver
000062851 951__ $$a2020-11-05-08:19:21
000062851 980__ $$aARTICLE